BofA lowered the firm’s price target on Acadia Pharmaceuticals (ACAD) to $18 from $19 and keeps a Neutral rating on the shares. The firm updated models in smid-cap biotech as part of a Q1 earnings preview.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- ACADIA Pharmaceuticals: Promising Growth Potential and Strategic Stability Reinforce Buy Rating
- Insider Moves: ACADIA, EPR, Apple, Kratos, Energy Fuels
- Acadia Pharmaceuticals assumed with an Equal Weight at Morgan Stanley
- Balanced Outlook for ACADIA Pharmaceuticals Amid Uncertain Long-term Growth Prospects
- Acadia Pharmaceuticals, Saniona announce results from ACP-711 cohorts